uracil has been researched along with Cardiovascular Diseases in 29 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Approximately 5,400 men and women with type 2 diabetes and ACS (acute myocardial infarction or unstable angina) are being recruited and will be followed up for up to 4." | 6.76 | EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients wi ( Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Fleck, P; Heller, S; Mehta, C; Nissen, SE; Perez, A; White, WB; Wilson, C; Zannad, F, 2011) |
| "The EXAMINE trial randomized 5380 patients with type 2 diabetes (T2DM) and a recent acute coronary syndrome (ACS) event, in 49 countries, to double-blind treatment with alogliptin or placebo in addition to standard of care." | 5.24 | Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. ( Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Gourlie, NM; Heller, SR; Kupfer, S; Liu, Y; Mehta, CR; Nissen, SE; White, WB; Wilson, CA; Zannad, F, 2017) |
| "We randomly assigned patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 to 90 days to receive alogliptin or placebo in addition to existing antihyperglycemic and cardiovascular drug therapy." | 5.17 | Alogliptin after acute coronary syndrome in patients with type 2 diabetes. ( Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Fleck, PR; Heller, SR; Kupfer, S; Mehta, CR; Nissen, SE; Perez, AT; White, WB; Wilson, C; Zannad, F, 2013) |
| "In patients with type 2 diabetes and a recent ACS, the risk of CV death was higher after a postrandomization, nonfatal CV event, particularly heart failure, compared with those who did not experience a CV event." | 2.82 | Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. ( Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Fleck, PR; Heller, SR; Kupfer, S; Lei, L; Mehta, CR; Nissen, SE; White, WB; Wilson, CA; Zannad, F, 2016) |
| "We evaluated the incidence of CV events in patients treated with alogliptin, placebo or comparator antihyperglycaemic drugs in the clinical trial database for alogliptin using the composite major adverse cardiovascular event (MACE) endpoints of CV death, non-fatal myocardial infarction and non-fatal stroke." | 2.78 | Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. ( Fleck, P; Hisada, M; Menon, V; Munsaka, M; Pratley, R; White, WB; Wilson, C, 2013) |
| "Approximately 5,400 men and women with type 2 diabetes and ACS (acute myocardial infarction or unstable angina) are being recruited and will be followed up for up to 4." | 2.76 | EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients wi ( Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Fleck, P; Heller, S; Mehta, C; Nissen, SE; Perez, A; White, WB; Wilson, C; Zannad, F, 2011) |
| " This review summarizes the current state of knowledge of FIC with special regard to proposed pathogenetic models (coronary vasospasm, endothelium and cardiomyocytes damage, toxic metabolites, dihydropyrimidine dehydrogenase deficiency); risk and predictive factors; efficacy and usefulness in detection of laboratory markers, electrocardiographic changes and cardiac imaging; and specific treatment, including a novel agent, uridine triacetate." | 2.58 | Fluoropyrimidine-induced cardiotoxicity. ( Aglietta, M; Bonzano, A; Cagnazzo, C; Depetris, I; Filippi, R; Leone, F; Marino, D, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.45) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (6.90) | 29.6817 |
| 2010's | 25 (86.21) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Nabavizadeh, P | 1 |
| Steen, DL | 1 |
| Depetris, I | 1 |
| Marino, D | 1 |
| Bonzano, A | 1 |
| Cagnazzo, C | 1 |
| Filippi, R | 1 |
| Aglietta, M | 1 |
| Leone, F | 1 |
| Sano, M | 1 |
| White, WB | 7 |
| Pratley, R | 1 |
| Fleck, P | 3 |
| Munsaka, M | 1 |
| Hisada, M | 1 |
| Wilson, C | 4 |
| Menon, V | 1 |
| Cannon, CP | 5 |
| Heller, SR | 3 |
| Nissen, SE | 4 |
| Bergenstal, RM | 4 |
| Bakris, GL | 4 |
| Perez, AT | 1 |
| Fleck, PR | 2 |
| Mehta, CR | 3 |
| Kupfer, S | 3 |
| Cushman, WC | 4 |
| Zannad, F | 5 |
| Cohen, D | 1 |
| Lim, GB | 1 |
| Greenhill, C | 1 |
| Mitka, M | 1 |
| Standl, E | 1 |
| Mullard, A | 1 |
| Doggrell, SA | 1 |
| Dimmitt, SB | 1 |
| Davis, TM | 1 |
| Gallwitz, B | 1 |
| Nitschmann, S | 1 |
| Del Prato, S | 1 |
| Camisasca, R | 1 |
| Koska, J | 1 |
| Sands, M | 1 |
| Burciu, C | 1 |
| Reaven, P | 1 |
| Baker, WL | 1 |
| Bonora, E | 1 |
| Cigolini, M | 1 |
| Wilson, CA | 2 |
| Lei, L | 1 |
| Schernthaner, G | 1 |
| Cahn, A | 1 |
| Raz, I | 1 |
| Simó, R | 1 |
| Hernández, C | 1 |
| Mannucci, E | 1 |
| Monami, M | 1 |
| Liu, Y | 2 |
| Gourlie, NM | 1 |
| Bergmark, BA | 1 |
| Jarolim, P | 1 |
| Bonaca, MP | 1 |
| Morrow, DA | 1 |
| Gersch, C | 1 |
| Palii, SP | 1 |
| Kim, KM | 1 |
| Angerhofer, A | 1 |
| Johnson, RJ | 1 |
| Henderson, GN | 1 |
| Viereck, C | 1 |
| Boudes, P | 1 |
| Heller, S | 1 |
| Mehta, C | 1 |
| Perez, A | 1 |
| Jakobsen, A | 1 |
| Mortensen, JP | 1 |
| Bisgaard, C | 1 |
| Lindebjerg, J | 1 |
| Rafaelsen, SR | 1 |
| Bendtsen, VO | 1 |
| Zabel'ian, OM | 1 |
| Leshchinskiĭ, LA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome[NCT00968708] | Phase 3 | 5,380 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary Major Adverse Cardiac Events were defined as a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 11.8 |
| Alogliptin | 11.3 |
Secondary MACE composite consisted of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or urgent revascularization due to unstable angina; these events were adjudicated by an independent cardiovascular endpoint committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-of date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 13.4 |
| Alogliptin | 12.7 |
6 reviews available for uracil and Cardiovascular Diseases
| Article | Year |
|---|---|
Fluoropyrimidine-induced cardiotoxicity.
Topics: Acetates; Capecitabine; Cardiotoxicity; Cardiovascular Diseases; Drug Combinations; Fluorouracil; Hu | 2018 |
Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Femal | 2019 |
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Topics: Adamantane; Animals; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; | 2015 |
Cardiovascular Effects of Incretin-Based Therapies.
Topics: Adamantane; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Melli | 2016 |
DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
Topics: Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Di | 2016 |
Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV | 2017 |
9 trials available for uracil and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dia | 2013 |
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
Topics: Aged; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV | 2013 |
Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase | 2014 |
Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Hypoglyce | 2016 |
Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Cohort Studies; Combined Modality Therapy; Diabete | 2017 |
Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial.
Topics: Acute Coronary Syndrome; Adiponectin; Aged; Biomarkers; Cardiovascular Diseases; Cohort Studies; Dia | 2017 |
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients wi
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, | 2011 |
A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cardiovascular | 2008 |
[Comparative evaluation of the effectiveness of 2 drug combinations (strophanthin and potassium orotate, strophanthin and methyluracil) in circulatory insufficiency].
Topics: Adult; Aged; Cardiovascular Diseases; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Dr | 1980 |
14 other studies available for uracil and Cardiovascular Diseases
| Article | Year |
|---|---|
Highlights from the European society of cardiology congress 2020.
Topics: Atrial Fibrillation; Benzhydryl Compounds; Benzylamines; Cardiomyopathy, Hypertrophic; Cardiovascula | 2021 |
New oral hypoglycaemics fail to show cardiovascular benefits.
Topics: Adamantane; Cardiovascular Diseases; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypogly | 2013 |
Diabetes: Cardiovascular safety of 'gliptin' therapy.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipept | 2013 |
Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipept | 2013 |
New drugs improve glycemic control in type 2 diabetes, but improving heart health remains elusive.
Topics: Adamantane; Blood Glucose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type | 2013 |
Saxagliptin, alogliptin, and cardiovascular outcomes.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipept | 2014 |
Outcome results renew debate about diabetes drug development.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides | 2013 |
Gliptins - do they increase cardiovascular risk or benefit?
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipept | 2014 |
Dipeptidyl peptidase-4 inhibitors and cardiovascular safety.
Topics: Adamantane; Blood Glucose; Cardiovascular Diseases; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; | 2014 |
[New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipept | 2014 |
Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV | 2016 |
New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
Topics: Adamantane; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Di | 2016 |
Inactivation of nitric oxide by uric acid.
Topics: Cardiovascular Diseases; Chromatography, Liquid; Endothelial Cells; Glutathione; Humans; Hydrogen Pe | 2008 |
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type | 2011 |